Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
Background Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Renal Failure |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/0886022X.2020.1801466 |
id |
doaj-5e8910168bb446eab64e6aeea97cdee1 |
---|---|
record_format |
Article |
spelling |
doaj-5e8910168bb446eab64e6aeea97cdee12021-03-18T14:42:06ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492020-01-0142183684410.1080/0886022X.2020.18014661801466Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitorsSaid Darawshi0Hiba Yaseen1Yuri Gorelik2Caroline Faor3Auryan Szalat4Zaid Abassi5Samuel N. Heyman6Mogher Khamaisi7Department of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITClinical Research Institute, Rambam Health Care CampusDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITDepartment of Medicine, Hadassah Hebrew University HospitalDepartment of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion-IITDepartment of Medicine, Hadassah Hebrew University HospitalDepartment of Medicine D, Ruth & Bruce Rappaport Faculty of Medicine, Rambam Health Care Campus, Technion-IITBackground Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia leading to acute tubular injury (ATI). The aim or this study was to prospectively assess the pathophysiology of acute kidney injury (AKI) in patients hospitalized while on SGLT2i, differing ATI from pre-renal causes using renal biomarkers. Methods Serum and urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Ischemia Molecule (KIM)-1, markers of distal and proximal tubular injury, respectively, were determined in 46 diabetic patients who were on SGLT2i upon hospitalization with an acute illness. Results Serum and urine NGAL, but not KIM-1, were significantly increased in 21 of the patients who presented with AKI upon admission, as compared with 25 patients that maintained kidney function. Both serum and urinary NGAL correlated with the degree of impaired renal function, which in many cases was likely the result of additional acute renal perturbations, such as sepsis. Conclusions Increased urinary and serum NGAL indicates that ATI, principally affecting distal tubular segments, may develop in some of the patients hospitalized with an acute illness and AKI while on SGLT2i. It is suggested that intensified medullary hypoxia by SGLT2i might be detrimental in this injury. By contrast, concomitantly unaltered KIM-1 might reflect improved cortical oxygenation by SGLT2i, and may explain an overall reduced risk of AKI with SGLT1i in large series. The independent potential of SGLT2i to inflict medullary hypoxic damage should be explored further.http://dx.doi.org/10.1080/0886022X.2020.1801466acute kidney failuresglt2 inhibitorshypoxiabiomarkerngalkim-1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Said Darawshi Hiba Yaseen Yuri Gorelik Caroline Faor Auryan Szalat Zaid Abassi Samuel N. Heyman Mogher Khamaisi |
spellingShingle |
Said Darawshi Hiba Yaseen Yuri Gorelik Caroline Faor Auryan Szalat Zaid Abassi Samuel N. Heyman Mogher Khamaisi Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors Renal Failure acute kidney failure sglt2 inhibitors hypoxia biomarker ngal kim-1 |
author_facet |
Said Darawshi Hiba Yaseen Yuri Gorelik Caroline Faor Auryan Szalat Zaid Abassi Samuel N. Heyman Mogher Khamaisi |
author_sort |
Said Darawshi |
title |
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors |
title_short |
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors |
title_full |
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors |
title_fullStr |
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors |
title_full_unstemmed |
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors |
title_sort |
biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (aki) while on sglt2 inhibitors |
publisher |
Taylor & Francis Group |
series |
Renal Failure |
issn |
0886-022X 1525-6049 |
publishDate |
2020-01-01 |
description |
Background Inhibitors of sodium-glucose co-transporter-2 (SGLT2i) were found to improve renal outcome in diabetic patients in large prospective randomized trials. Yet, SGLT2i may acutely reduce kidney function through volume depletion, altered glomerular hemodynamics or intensified medullary hypoxia leading to acute tubular injury (ATI). The aim or this study was to prospectively assess the pathophysiology of acute kidney injury (AKI) in patients hospitalized while on SGLT2i, differing ATI from pre-renal causes using renal biomarkers. Methods Serum and urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Ischemia Molecule (KIM)-1, markers of distal and proximal tubular injury, respectively, were determined in 46 diabetic patients who were on SGLT2i upon hospitalization with an acute illness. Results Serum and urine NGAL, but not KIM-1, were significantly increased in 21 of the patients who presented with AKI upon admission, as compared with 25 patients that maintained kidney function. Both serum and urinary NGAL correlated with the degree of impaired renal function, which in many cases was likely the result of additional acute renal perturbations, such as sepsis. Conclusions Increased urinary and serum NGAL indicates that ATI, principally affecting distal tubular segments, may develop in some of the patients hospitalized with an acute illness and AKI while on SGLT2i. It is suggested that intensified medullary hypoxia by SGLT2i might be detrimental in this injury. By contrast, concomitantly unaltered KIM-1 might reflect improved cortical oxygenation by SGLT2i, and may explain an overall reduced risk of AKI with SGLT1i in large series. The independent potential of SGLT2i to inflict medullary hypoxic damage should be explored further. |
topic |
acute kidney failure sglt2 inhibitors hypoxia biomarker ngal kim-1 |
url |
http://dx.doi.org/10.1080/0886022X.2020.1801466 |
work_keys_str_mv |
AT saiddarawshi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT hibayaseen biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT yurigorelik biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT carolinefaor biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT auryanszalat biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT zaidabassi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT samuelnheyman biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors AT mogherkhamaisi biomarkerevidencefordistaltubulardamagebutcorticalsparinginhospitalizeddiabeticpatientswithacutekidneyinjuryakiwhileonsglt2inhibitors |
_version_ |
1724215893159837696 |